首页 | 本学科首页   官方微博 | 高级检索  
     

RhoA-ROCK通路在血管紧张素Ⅱ刺激人胚肺成纤维细胞表达结缔组织生长因子中的作用
引用本文:Meng Y,Cai SX,Tong WC,Li X. RhoA-ROCK通路在血管紧张素Ⅱ刺激人胚肺成纤维细胞表达结缔组织生长因子中的作用[J]. 中华医学杂志, 2011, 91(16): 1125-1129. DOI: 10.3760/cma.j.issn.0376-2491.2011.16.013
作者姓名:Meng Y  Cai SX  Tong WC  Li X
作者单位:1. 南方医科大学南方医院呼吸内科,广州,510515
2. 南方医科大学南方医院急诊科,广州,510515
基金项目:国家自然科学基金,广东省医学科学技术研究基金
摘    要:
目的 探讨RhoA-ROCK通路在血管紧张素Ⅱ(AngⅡ)刺激人胚肺成纤维细胞(HFL-1)表达结缔组织生长因子(CTGF)中的作用.方法 培养HFL-1,设置无刺激对照组、AngⅡ组(10-7 mol/L的AngⅡ刺激)、Irbesartan+AngⅡ组(以10-6 mol/L的AT-1受体拮抗剂Irbesartan预处理1 h后再予10-7 mol/L的AngⅡ刺激)和ROCK抑制剂Y27632+AngⅡ组(10-6 mol/L的Y27632预处理1 h后再予10-7 mol/L的AngⅡ刺激).利用Western印迹和QuantiGene多基因定量方法检测RhoA-ROCK激活及下游因子CTGF表达情况.结果 观察Irbesartan对AngⅡ诱导CTGF蛋白表达的实验,结果:AngⅡ组CTGF蛋白表达较对照组增强(0.89±0.05比0.48±0.10,P<0.01),Irbesartan+AngⅡ组(0.72±0.05)较AngⅡ组减弱(P<0.05).AngⅡ组RhoA蛋白表达较对照组增强(3.40±0.46比1.77±0.37,P<0.01),Irbesartan+AngⅡ组(2.27±0.45)较AngⅡ组减弱(P<0.05).重新培养细胞留取标本观察Y27632对AngⅡ诱导CTGF蛋白表达的影响,结果:AngⅡ组CTGF蛋白表达较对照组增强(0.62±0.15比0.16±0.05,P<0.01),Y27632+AngⅡ组(0.17±0.04)较AngⅡ组减弱(P<0.01).从基因水平重复上述实验,结果:AngⅡ组CTGF mRNA表达较对照组增强(1.16±0.06比1.00±0.01,P<0.01),Irbesartan+AngⅡ组(0.99±0.07)较AngⅡ组减弱(P<0.01),Y27632+AngⅡ组(1.04±0.08)较AngⅡ组减弱(P<0.05);AngⅡ组RhoA mRNA表达较对照组增强(1.21±0.07比1.00±0.06,P<0.01),Irbesartan+AngⅡ组(1.00±0.12)较AngⅡ组减弱(P<0.05),Y27632+AngⅡ组(1.10±0.05)与AngⅡ组比较差异无统计学意义(P>0.05).结论 AngⅡ通过AT-1受体诱导HFL-1细胞CTGF蛋白和mRNA表达,RhoA-Rock通路参与其中.
Abstract:
Objective To explore the production of connective tissue growth factor(CTGF)by Angiotensin Ⅱ(Ang Ⅱ)in human embryonic lung fibroblast via the RhoA-ROCK pathway. Methods Human embryonic lung fibroblast(HFL-1)was divided into 4 groups:(1)control group:no stimulation;(2)AngⅡgroup:stimulation of AngⅡ(10-7 mol/L);(3)Irbesartan plus Ang Ⅱ group:stimulation by Ang Ⅱ(10-7 mol/L)with AT-1 receptor antagonist irbesartan(10-6 mol/L)pre-treatment;(4)Irbesartan plus Ang Ⅱ group:stimulation by Ang Ⅱ(10-7 mol/L)with ROCK inhibitor Y27632(10-6 mol/L)pretreatment.Then the products of protein and RNA were collected.Western blot and QuantiGene were used to detect the activation of RhoA-Rock pathway and CTGF.Results Exploring the affect of irbesartan on Ang Ⅱ through the Western blot analysis of CTGF and RhoA protein expression:the CTGF level was up-regulated by AngⅡ(0.89±0.05 vs control 0.48 ±0.10,P <0.01).Such an effect was markedly blocked by a pretreatment of irbesartan(0.72 ± 0.05,P<0.05).After the use of Ang Ⅱ,the expression of RhoA protein was significantly enhanced(3.40 ± 0.46 vs control 1.77 ± 0.37,P<0.01)and blunted by a pretreatment of irbesartan(2.27 ± 0.45,P<0.05).The Western blot analysis of CTGF protein expression showed that Ang Ⅱ caused a robust increase in CTGF(0.62 ± 0.15 vs control 0.16 ± 0.05,P<0.01).Such an effect was markedly blocked by a pretreatment of Y27632(0.17 ± 0.04,P<0.01).The result was similar at the gene level.Ang Ⅱ significantly increased the expression of CTGF mRNA(1.16 ± 0.06 vs control 1.00 ± 0.01,P<0.01).And it was markedly blocked by a pretreatment of irbesartan(0.99 ±0.07,P<0.01)or Y27632(1.04 ±0.08,P<0.05).AngⅡ significantly increased the expression of RhoA mRNA(1.21 ± 0.07 vs control 1.00 ± 0.06,P<0.01).And it was markedly blocked by a pretreatment of irbesartan(1.00 ± 0.12,P<0.05)but not Y27632(1.10 ± 0.05,P>0.05).Conclusion Ang Ⅱ activates HFL-1 to produce CTGF through the AT-1 receptor.And the RhoA-Rock pathway is involved.

关 键 词:血管紧张素Ⅱ  成纤维细胞  肺纤维化  RhoA-ROCK通路  结缔组织生长因子

Production of connective tissue growth factor by angiotensin II in human embryonic lung fibroblast via RhoA-ROCK pathway
Meng Ying,Cai Shao-xi,Tong Wan-cheng,Li Xu. Production of connective tissue growth factor by angiotensin II in human embryonic lung fibroblast via RhoA-ROCK pathway[J]. Zhonghua yi xue za zhi, 2011, 91(16): 1125-1129. DOI: 10.3760/cma.j.issn.0376-2491.2011.16.013
Authors:Meng Ying  Cai Shao-xi  Tong Wan-cheng  Li Xu
Affiliation:Department of Respiratory Diseases, Nanfang Hospital, South Medical University, Guangzhou 510515, China.
Abstract:
Objective To explore the production of connective tissue growth factor(CTGF)by Angiotensin Ⅱ(Ang Ⅱ)in human embryonic lung fibroblast via the RhoA-ROCK pathway. Methods Human embryonic lung fibroblast(HFL-1)was divided into 4 groups:(1)control group:no stimulation;(2)AngⅡgroup:stimulation of AngⅡ(10-7 mol/L);(3)Irbesartan plus Ang Ⅱ group:stimulation by Ang Ⅱ(10-7 mol/L)with AT-1 receptor antagonist irbesartan(10-6 mol/L)pre-treatment;(4)Irbesartan plus Ang Ⅱ group:stimulation by Ang Ⅱ(10-7 mol/L)with ROCK inhibitor Y27632(10-6 mol/L)pretreatment.Then the products of protein and RNA were collected.Western blot and QuantiGene were used to detect the activation of RhoA-Rock pathway and CTGF.Results Exploring the affect of irbesartan on Ang Ⅱ through the Western blot analysis of CTGF and RhoA protein expression:the CTGF level was up-regulated by AngⅡ(0.89±0.05 vs control 0.48 ±0.10,P <0.01).Such an effect was markedly blocked by a pretreatment of irbesartan(0.72 ± 0.05,P<0.05).After the use of Ang Ⅱ,the expression of RhoA protein was significantly enhanced(3.40 ± 0.46 vs control 1.77 ± 0.37,P<0.01)and blunted by a pretreatment of irbesartan(2.27 ± 0.45,P<0.05).The Western blot analysis of CTGF protein expression showed that Ang Ⅱ caused a robust increase in CTGF(0.62 ± 0.15 vs control 0.16 ± 0.05,P<0.01).Such an effect was markedly blocked by a pretreatment of Y27632(0.17 ± 0.04,P<0.01).The result was similar at the gene level.Ang Ⅱ significantly increased the expression of CTGF mRNA(1.16 ± 0.06 vs control 1.00 ± 0.01,P<0.01).And it was markedly blocked by a pretreatment of irbesartan(0.99 ±0.07,P<0.01)or Y27632(1.04 ±0.08,P<0.05).AngⅡ significantly increased the expression of RhoA mRNA(1.21 ± 0.07 vs control 1.00 ± 0.06,P<0.01).And it was markedly blocked by a pretreatment of irbesartan(1.00 ± 0.12,P<0.05)but not Y27632(1.10 ± 0.05,P>0.05).Conclusion Ang Ⅱ activates HFL-1 to produce CTGF through the AT-1 receptor.And the RhoA-Rock pathway is involved.
Keywords:Angiotensin Ⅱ  Fibroblast  Pulmonary fibrosis  RhoA-ROCK pathway  Connective tissue growth factor
本文献已被 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号